Article Information
History
- November 23, 2020.
Article Versions
- You are currently viewing Version 1 of this article (November 23, 2020 - 10:30).
- Version 2 (December 12, 2020 - 17:33).
- Version 3 (January 20, 2021 - 11:54).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- 1Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México (ICN-UNAM). A. P. 70–543, 04510, México City, México
- 2Myriad Pharmaceuticals Limited, Unit 3, 36 Greenpark Rd, Penrose, 1061, Auckland, New Zealand
- 3Center of Excellence for the acceleration of HArm Reduction (CoEHAR) University of Catania, Italy
- ↵*Corresponding author; email: sussman{at}nucleares.unam.mx